相似文献
1
Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome.
Blood Adv. 2020 May 26;4(10):2119-2122. doi: 10.1182/bloodadvances.2020001626.
2
Intrathecal Chemotherapy as a Potential Treatment for Steroid-refractory Immune Effector Cell-associated Neurotoxicity Syndrome.
Anticancer Res. 2022 Aug;42(8):3853-3856. doi: 10.21873/anticanres.15876.
3
Neurological Complications of CAR T Cell Therapy.
Curr Oncol Rep. 2020 Jul 1;22(8):83. doi: 10.1007/s11912-020-00935-6.
4
Intrathecal hydrocortisone for treatment of children and young adults with CAR T-cell immune-effector cell-associated neurotoxicity syndrome.
Pediatr Blood Cancer. 2024 Jan;71(1):e30741. doi: 10.1002/pbc.30741. Epub 2023 Oct 27.
5
Stuttering as the first sign of CAR-T-cell-related encephalopathy syndrome (CRES).
J Cancer Res Clin Oncol. 2019 Jul;145(7):1917-1918. doi: 10.1007/s00432-018-2818-y. Epub 2018 Dec 11.
6
A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.
Neurol Clin. 2020 Nov;38(4):953-963. doi: 10.1016/j.ncl.2020.08.001. Epub 2020 Sep 12.
7
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.
Blood. 2019 May 16;133(20):2212-2221. doi: 10.1182/blood-2018-12-893396. Epub 2019 Feb 26.
8
Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome.
JAMA Oncol. 2022 May 1;8(5):773-775. doi: 10.1001/jamaoncol.2022.0070.
9
Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
Expert Opin Biol Ther. 2019 Nov;19(11):1157-1164. doi: 10.1080/14712598.2019.1644316. Epub 2019 Jul 25.
10
Targeting TAK1 in microglia to treat CAR T cell neurotoxicity.
Nat Cancer. 2024 Aug;5(8):1143-1144. doi: 10.1038/s43018-024-00765-6.
引用本文的文献
1
[Chimeric antigen receptor T-cells for patients with hematologic malignancies].
Z Rheumatol. 2025 Sep 4. doi: 10.1007/s00393-025-01703-2.
2
Neurological complications of CAR T cell therapy for cancers.
Nat Rev Neurol. 2025 Jun 25. doi: 10.1038/s41582-025-01112-8.
3
The efficacy and applicability of chimeric antigen receptor (CAR) T cell-based regimens for primary bone tumors: A comprehensive review of current evidence.
J Bone Oncol. 2024 Sep 22;48:100635. doi: 10.1016/j.jbo.2024.100635. eCollection 2024 Oct.
4
Intrathecal chemotherapy as treatment for chimeric antigen receptor T cell (CAR T) therapy associated neurotoxicity.
Bone Marrow Transplant. 2024 Dec;59(12):1783-1785. doi: 10.1038/s41409-024-02417-w. Epub 2024 Sep 19.
5
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy.
Semin Immunopathol. 2024 Jul 16;46(3-4):5. doi: 10.1007/s00281-024-01013-w.
6
Mechanisms and management of CAR T toxicity.
Front Oncol. 2024 May 21;14:1396490. doi: 10.3389/fonc.2024.1396490. eCollection 2024.
7
Case report: Rapid resolution of grade IV ICANS after first line intrathecal chemotherapy with methotrexate, cytarabine and dexamethasone.
Front Immunol. 2024 May 3;15:1380451. doi: 10.3389/fimmu.2024.1380451. eCollection 2024.
8
Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update.
Crit Care. 2024 Mar 5;28(1):69. doi: 10.1186/s13054-024-04851-0.
9
Chimeric Antigen Receptor T Cell Therapy for Acute Leukemia.
Blood Cell Ther. 2023 Nov 25;6(4):145-150. doi: 10.31547/bct-2023-028.
10
Intrathecal hydrocortisone for treatment of children and young adults with CAR T-cell immune-effector cell-associated neurotoxicity syndrome.
Pediatr Blood Cancer. 2024 Jan;71(1):e30741. doi: 10.1002/pbc.30741. Epub 2023 Oct 27.
本文引用的文献
1
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia.
J Clin Oncol. 2020 Feb 10;38(5):415-422. doi: 10.1200/JCO.19.01892. Epub 2019 Dec 9.
2
CAR-T-cell neurotoxicity: hope is on the horizon.
Blood. 2019 May 16;133(20):2114-2116. doi: 10.1182/blood-2019-03-900985.
3
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.
Blood. 2019 May 16;133(20):2212-2221. doi: 10.1182/blood-2018-12-893396. Epub 2019 Feb 26.
4
CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions.
J Natl Cancer Inst. 2019 Jul 1;111(7):646-654. doi: 10.1093/jnci/djz017.
5
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25.
6
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.
Cancer Discov. 2018 Aug;8(8):958-971. doi: 10.1158/2159-8290.CD-17-1319. Epub 2018 Jun 7.
7
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells.
Nat Med. 2018 Jun;24(6):739-748. doi: 10.1038/s41591-018-0036-4. Epub 2018 May 28.
8
Fludarabine and neurotoxicity in engineered T-cell therapy.
Gene Ther. 2018 Jun;25(3):176-191. doi: 10.1038/s41434-018-0019-6. Epub 2018 May 7.
9
Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy.
Biomark Res. 2018 Jan 22;6:4. doi: 10.1186/s40364-018-0116-0. eCollection 2018.
10
JCAR015 in ALL: A Root-Cause Investigation.
Cancer Discov. 2018 Jan;8(1):4-5. doi: 10.1158/2159-8290.CD-NB2017-169. Epub 2017 Dec 5.
Zotero 插件